These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 6764986)

  • 1. [Antibody formation and preservation against the envelope antigens of influenza virus subtype A(H3N2) after infection and vaccination].
    Stumpa A; Tůmová B
    Tr Inst Im Pastera; 1982; 59():23-8. PubMed ID: 6764986
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza.
    Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H
    Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic.
    Stumpa A; Cihla F; Tůmová B; Husek V; Slezácek J
    Acta Virol; 1979 Sep; 23(5):443-5. PubMed ID: 42307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccine 2008-2009.
    Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroepidemiologic study on influenza A (H1N1) virus infection among school children after an "antigenic shift" from A (H3N2) to a (H1N1) in Kukuoka of southern Japan in 1978.
    Tokugawa K; Ueda K; Sakoh M; Yoshikawa H; Nonaka S
    Pediatr Infect Dis J; 1987 Aug; 6(8):761-2. PubMed ID: 3670940
    [No Abstract]   [Full Text] [Related]  

  • 6. [Inactivated influenza vaccine (H1N1, H3N2, H3N1) - antibody response and protective effect in the influenza epidemic H1N1 in 1979 (author's transl)].
    Bruj J; Skocil V; Farník J; Hronovský F; Síp J
    Cesk Epidemiol Mikrobiol Imunol; 1981 Sep; 30(5):287-93. PubMed ID: 6456837
    [No Abstract]   [Full Text] [Related]  

  • 7. Antigenic variation of recent influenza A(H3N2) viruses.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1988 Jan; 37(3):38-40, 46-7. PubMed ID: 3122010
    [No Abstract]   [Full Text] [Related]  

  • 8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serologic survey of human type A influenza virus infection following 10-year periods of prevalence of H3N2 strains].
    Profeta ML; De Vito D; Fasan M
    Boll Ist Sieroter Milan; 1979 Jan; 57(6):690-9. PubMed ID: 552822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL
    J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of seroconversion after vaccination against influenza during the epidemic season 1991-1992 in Poland].
    Brydak L; Rudnicka H
    Przegl Epidemiol; 1993; 47(3):275-83. PubMed ID: 8234846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live tissue culture influenza vaccine for oral administration. I. Specific immune response to monovaccine A (H3N2) in volunteers.
    Alekseeva AK; Andzhaparidze OG; Gracheva EN; Sidorova LA; Melnikova SK
    Acta Virol; 1979 Jan; 23(1):59-66. PubMed ID: 35960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence vaccination: comparison of the effectiveness of two different vaccines].
    Kuwert E; Thraenhart O; Werner J; Höher PG
    Med Klin; 1980 Oct; 75(21):755-8. PubMed ID: 7453623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of the elution inhibition reaction for detecting antineuraminidase antibodies in the sera of persons inoculated with inactivated influenza vaccine].
    Briantseva EA
    Tr Inst Im Pastera; 1982; 59():59-62. PubMed ID: 6764988
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antigenic relationship between influenza A (H3N2) strains circulating in Argentina and vaccine strains].
    Savy VL; Baumeister EG; Pontoriero AV
    Medicina (B Aires); 1999; 59(3):225-30. PubMed ID: 10451559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statement on influenza vaccination for the 2007-2008 season. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Jul; 33(ACS-7):1-38. PubMed ID: 17663034
    [No Abstract]   [Full Text] [Related]  

  • 18. Canadian influenza serosurvey prior to the 1992-1993 season.
    Can Commun Dis Rep; 1992 Nov; 18(22):161-6. PubMed ID: 1291010
    [No Abstract]   [Full Text] [Related]  

  • 19. [Formation and persistence of antibodies against envelope antigens of influenza virus after vaccination by formolized monovaccine (author's transl)].
    Stumpa A; Bruj J; Tůmová B; Skocil V
    Cesk Epidemiol Mikrobiol Imunol; 1978 Feb; 27(1):29-37. PubMed ID: 149598
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccination-induced HI antibody response to intraepidemic influenza A(H3N2) virus variants of the 1996-1997 epidemic season.
    Pyhälä R; Ikonen N; Santanen R; Haanpää M; Visakorpi R; Jäppinen P; Valle M
    J Med Virol; 2001 Nov; 65(3):584-9. PubMed ID: 11596097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.